Skip to content

Effects of premedications for CAG on patients anxiety,complications and procedure time

Comparison between the effects of prodrugs with placebo for CAG on patient’s anxiety,complications and procedure time in Imam Khomeini hospital in Ardabil in 2013:a randomized single blind clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013102115096N1
Enrollment
150
Registered
2013-11-15
Start date
2013-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac catheterization. Angina Pectoris

Interventions

Intervention 1: In the first group, hemodynamic status one hour before the procedure is controlled then inject pre-medication diazepam ( 5 mg ) , promethazine ( 25 mg ) intramuscular and intravenous
Treatment - Drugs
Placebo
In the first group, hemodynamic status one hour before the procedure is controlled then inject pre-medication diazepam ( 5 mg ) , promethazine ( 25 mg ) intramuscular and intravenous hydrocortisone
In the second group, hemodynamic status one hour before the procedure is controlled then intravenous midazolam (0.02 mg/kg) inject at the arrival in the angiography room and during angiography. Anxiet
In the third group of drugs, hemodynamic status one hour before the procedure is controlled then intravenous normal saline ( 2 ml ) is injected half an hour before angiography and during angiography.

Sponsors

Vice chancellor for research, Ardebil University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: coronary angiography were have been for the first time; age between 35-75 years old; have just undergone coronary angiography without right heart catheterization; the patients before angiography are not underwent other invasive procedures such as transesophageal echocardiography. Exclusion criteria: the development of new myocardial infarction ( within weeks ); the risk of severe heart failure and valvular and congenital heart disease; hemodynamic instability; risk of severe anxiety disorder.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Anxiety level. Timepoint: During the angiography. Method of measurement: Spielberger state-trait anxiety inventory.;Angiography complications. Timepoint: During the angiography and one week after angiography. Method of measurement: Dagnosis with clinic and paraclinic evaluations.;Angiography time. Timepoint: During the angiography. Method of measurement: Measurment in minutes.

Secondary

MeasureTime frame
Hemodynamic state. Timepoint: One hour before and in during the angiography. Method of measurement: Control of pulse rate, respiratory rate, body tempreture, systolic and diastolic blood pressures.;Contrast volume. Timepoint: During the angiography. Method of measurement: Measurment in mili liter.;Access time. Timepoint: During the angiography. Method of measurement: Measurment in seconds.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mina Golalizadeh

Ardebil University of Medical Sciences

golalizadeh.star@gmail.com+98 45 1551 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026